Pharma sector under antitrust scrutiny in China
In June 2015, China pushed through a relatively bold liberalization of drug prices, moving from a regime where the government decides the prices or price ranges of the most commonly used drugs to a regime where the prices of most drugs are determined by market forces. Already then, the National Development and Reform Commission (NDRC)…